Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs AT&T Inc. (T) Price & Performance

Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs AT&T Inc. — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while AT&T Inc. trades at $24.49 (market cap $164.80B). The key difference: AT&T Inc. is far larger — about 3451.3× Cassava Sciences Inc's market cap, and AT&T Inc. pays a 4.62% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNAT
Market Cap
$47.75M$164.80B
Sector
HealthMedia
52-Week High
$4.64$29.62
52-Week Low
$0.87$20.49
Enterprise Value
-$34.93M$310.12B
Dividend Yield
4.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

AT&T Inc.

AT&T (T) trades at $23.80, up 0.38% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.69. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.65 exceeding the $0.59 estimate. Revenue grew to $125.65 billion in 2025, and net income surged to $21.95 billion, reflecting a robust profit margin of 17.47%. Recent news highlights fiber expansion and 5G network investments.

The outlook is positive, supported by improving cash flow, strategic investments, and a 4.8% dividend yield. However, risks include competitive pressure from new entrants like SpaceX's Starlink and high debt levels. Analyst sentiment is mixed but leans bullish, with 41% buy ratings. The stock presents a value opportunity with a low P/E of 7.85, but investors should monitor execution on growth initiatives.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About AT&T Inc.

AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.

Read more on T